Precision medicine in diabetes: a Consensus Report from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

[1]  L. Philipson,et al.  GCK-MODY in the US Monogenic Diabetes Registry: Description of 27 unpublished variants. , 2019, Diabetes research and clinical practice.

[2]  Samuel E. Jones,et al.  Frequency and phenotype of type 1 diabetes in the first six decades of life: a cross-sectional, genetically stratified survival analysis from UK Biobank , 2017, The lancet. Diabetes & endocrinology.

[3]  Alan R. Shuldiner,et al.  Common Variants in 40 Genes Assessed for Diabetes Incidence and Response to Metformin and Lifestyle Intervention in the Diabetes Prevention Program , 2010, Diabetes.

[4]  Timothy E. Reddy,et al.  Identification of HKDC1 and BACE2 as Genes Influencing Glycemic Traits During Pregnancy Through Genome-Wide Association Studies , 2013, Diabetes.

[5]  A. Hattersley,et al.  Heterozygous ABCC8 mutations are a cause of MODY , 2011, Diabetologia.

[6]  H. Siljander,et al.  Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial , 2008, The Lancet.

[7]  J. Krischer,et al.  Effect of Oral Insulin on Prevention of Diabetes in Relatives of Patients With Type 1 Diabetes: A Randomized Clinical Trial , 2017, JAMA.

[8]  H. Teede,et al.  Prognostic prediction models for pregnancy complications in women with gestational diabetes: a protocol for systematic review, critical appraisal and meta-analysis , 2019, Systematic Reviews.

[9]  A. Hattersley,et al.  Loss‐of‐Function CYP2C9 Variants Improve Therapeutic Response to Sulfonylureas in Type 2 Diabetes: A Go‐DARTS Study , 2010, Clinical pharmacology and therapeutics.

[10]  Manolis Kellis,et al.  Fine mapping of type 1 diabetes susceptibility loci and evidence for colocalization of causal variants with lymphoid gene enhancers , 2015, Nature Genetics.

[11]  Å. Lernmark,et al.  Staging Presymptomatic Type 1 Diabetes: A Scientific Statement of JDRF, the Endocrine Society, and the American Diabetes Association , 2015, Diabetes Care.

[12]  Catherine Kim,et al.  Gestational diabetes and the incidence of type 2 diabetes: a systematic review. , 2002, Diabetes care.

[13]  B. Shields,et al.  Prevalence of vascular complications among patients with glucokinase mutations and prolonged, mild hyperglycemia. , 2014, JAMA.

[14]  Ranking and characterization of established BMI and lipid associated loci as candidates for gene-environment interactions , 2017, PLoS genetics.

[15]  B. Shields,et al.  Type 1 diabetes defined by severe insulin deficiency occurs after 30 years of age and is commonly treated as type 2 diabetes , 2019, Diabetologia.

[16]  I. Tkáč,et al.  KCNJ11 gene E23K variant and therapeutic response to sulfonylureas. , 2012, European journal of internal medicine.

[17]  L. Groop,et al.  Absence of Islet Autoantibodies and Modestly Raised Glucose Values at Diabetes Diagnosis Should Lead to Testing for MODY: Lessons From a 5-Year Pediatric Swedish National Cohort Study , 2019, Diabetes Care.

[18]  Zhaoqian Liu,et al.  PPAR-γ2 and PTPRD gene polymorphisms influence type 2 diabetes patients' response to pioglitazone in China , 2012, Acta Pharmacologica Sinica.

[19]  M. Hsieh,et al.  Common polymorphisms of the peroxisome proliferator-activated receptor-gamma (Pro12Ala) and peroxisome proliferator-activated receptor-gamma coactivator-1 (Gly482Ser) and the response to pioglitazone in Chinese patients with type 2 diabetes mellitus. , 2010, Metabolism: clinical and experimental.

[20]  Within-trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. , 2003, Diabetes care.

[21]  H. Kuang,et al.  Association of sulfonylurea receptor 1 genotype with therapeutic response to gliclazide in type 2 diabetes. , 2007, Diabetes research and clinical practice.

[22]  I. Tkáč,et al.  Effect of sulphonylurea treatment on glycaemic control is related to TCF7L2 genotype in patients with type 2 diabetes , 2011, Diabetes, obesity & metabolism.

[23]  T. Hansen,et al.  Molecular genetics and phenotypic characteristics of MODY caused by hepatocyte nuclear factor 4α mutations in a large European collection , 2005, Diabetologia.

[24]  D. Hober,et al.  Enteroviral pathogenesis of type 1 diabetes: queries and answers. , 2013, Current opinion in infectious diseases.

[25]  E. Bonifacio,et al.  Primary Dietary Intervention Study to Reduce the Risk of Islet Autoimmunity in Children at Increased Risk for Type 1 Diabetes , 2011, Diabetes Care.

[26]  S. Fowler,et al.  The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. , 2006, The journals of gerontology. Series A, Biological sciences and medical sciences.

[27]  Peter Donnelly,et al.  Edinburgh Research Explorer Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes , 2022 .

[28]  J. Krischer,et al.  The use of intermediate endpoints in the design of type 1 diabetes prevention trials , 2013, Diabetologia.

[29]  R. Brinster,et al.  Somatic hypermutation of an immunoglobulin transgene in K transgenic mice , 1987, Nature.

[30]  Catherine C. Robertson,et al.  Type 1 Diabetes Risk in African-Ancestry Participants and Utility of an Ancestry-Specific Genetic Risk Score , 2019, Diabetes Care.

[31]  A. Hattersley,et al.  The effect of early, comprehensive genomic testing on clinical care in neonatal diabetes: an international cohort study , 2015, The Lancet.

[32]  W. Polonsky,et al.  Addressing diabetes distress in clinical care: a practical guide , 2019, Diabetic medicine : a journal of the British Diabetic Association.

[33]  Karla I. Galaviz,et al.  Long-term Sustainability of Diabetes Prevention Approaches: A Systematic Review and Meta-analysis of Randomized Clinical Trials , 2017, JAMA internal medicine.

[34]  L. Groop,et al.  Antibodies to Glutamic Acid Decarboxylase Reveal Latent Autoimmune Diabetes Mellitus in Adults With a Non—Insulin-Dependent Onset of Disease , 1993, Diabetes.

[35]  A. Hattersley,et al.  Analysis of cell‐free fetal DNA for non‐invasive prenatal diagnosis in a family with neonatal diabetes , 2016, Diabetic medicine : a journal of the British Diabetic Association.

[36]  A. Hattersley,et al.  Clinical features, diagnosis and management of maternally inherited diabetes and deafness (MIDD) associated with the 3243A>G mitochondrial point mutation , 2008, Diabetic medicine : a journal of the British Diabetic Association.

[37]  J. Ilonen,et al.  Infant Feeding in Relation to the Risk of Advanced Islet Autoimmunity and Type 1 Diabetes in Children With Increased Genetic Susceptibility: A Cohort Study , 2018, American journal of epidemiology.

[38]  A. Hattersley,et al.  Permanent neonatal diabetes due to mutations in KCNJ11 encoding Kir6.2: patient characteristics and initial response to sulfonylurea therapy. , 2004, Diabetes.

[39]  I. Tkáč,et al.  Association between TCF7L2 Genotype and Glycemic Control in Diabetic Patients Treated with Gliclazide , 2013, International journal of endocrinology.

[40]  Anil Poudel,et al.  Diabetes and Associated Cardiovascular Complications in American Indians/Alaskan Natives: A Review of Risks and Prevention Strategies , 2018, Journal of diabetes research.

[41]  L. Groop,et al.  Risk of diabetes-associated diseases in subgroups of patients with recent-onset diabetes: a 5-year follow-up study. , 2019, The lancet. Diabetes & endocrinology.

[42]  G. A. Fleming,et al.  Diabetes Digital App Technology: Benefits, Challenges, and Recommendations. A Consensus Report by the European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA) Diabetes Technology Working Group , 2019, Diabetes Care.

[43]  B. Shields,et al.  Disease progression and treatment response in data-driven subgroups of type 2 diabetes compared with models based on simple clinical features: an analysis using clinical trial data , 2019, The lancet. Diabetes & endocrinology.

[44]  M. Roizen,et al.  10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study , 2010 .

[45]  D. Scholtens,et al.  Genetics of Gestational Diabetes Mellitus and Maternal Metabolism , 2016, Current Diabetes Reports.

[46]  K. Ismail,et al.  The link between depression and diabetes: the search for shared mechanisms. , 2015, The lancet. Diabetes & endocrinology.

[47]  B. Shields,et al.  Frequency and phenotype of T1DM in the first six decades of life: a cross-sectional, genetically stratified survival analysis from UK Biobank , 2018 .

[48]  K. Polonsky,et al.  Standardization of C-peptide measurements. , 2008, Clinical chemistry.

[49]  E. Bonifacio,et al.  Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. , 2013, JAMA.

[50]  E. Gale.  European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes , 2004, The Lancet.

[51]  Shuzhong Zhang,et al.  Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. , 2007, The Journal of clinical investigation.

[52]  Stéphane Joost,et al.  Gene–obesogenic environment interactions in the UK Biobank study , 2017, International journal of epidemiology.

[53]  Xiping Xu,et al.  Ser1369Ala Variant in Sulfonylurea Receptor Gene ABCC8 Is Associated With Antidiabetic Efficacy of Gliclazide in Chinese Type 2 Diabetic Patients , 2008, Diabetes Care.

[54]  A. Hattersley,et al.  Genetic cause of hyperglycaemia and response to treatment in diabetes , 2003, The Lancet.

[55]  David M Nathan,et al.  10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. , 2009, Lancet.

[56]  D. Altshuler,et al.  Updated Genetic Score Based on 34 Confirmed Type 2 Diabetes Loci Is Associated With Diabetes Incidence and Regression to Normoglycemia in the Diabetes Prevention Program , 2011, Diabetes.

[57]  2. Classification and Diagnosis of Diabetes , 2016, Diabetes Care.

[58]  S. Jakobsen,et al.  Genetic Polymorphisms in Organic Cation Transporter 1 Attenuates Hepatic Metformin Exposure in Humans , 2017, Clinical pharmacology and therapeutics.

[59]  Miranda E. Kroehl,et al.  Erythrocyte membrane docosapentaenoic acid levels are associated with islet autoimmunity: the Diabetes Autoimmunity Study in the Young , 2014, Diabetologia.

[60]  M. McCarthy,et al.  Variation in TCF7L2 Influences Therapeutic Response to Sulfonylureas , 2007, Diabetes.

[61]  J. Ilonen,et al.  Hydrolyzed infant formula and early β-cell autoimmunity: a randomized clinical trial. , 2014, JAMA.

[62]  M. McCarthy,et al.  Reduced-Function SLC22A1 Polymorphisms Encoding Organic Cation Transporter 1 and Glycemic Response to Metformin: A GoDARTS Study , 2009, Diabetes.

[63]  F. Snoek,et al.  Constructs of depression and distress in diabetes: time for an appraisal. , 2015, The lancet. Diabetes & endocrinology.

[64]  Harald Baumeister,et al.  Depression and diabetes: treatment and health-care delivery. , 2015, The lancet. Diabetes & endocrinology.

[65]  B. Shields,et al.  The development and validation of a clinical prediction model to determine the probability of MODY in patients with young-onset diabetes , 2012, Diabetologia.

[66]  K. Vehik,et al.  Long-Term Outcome of Individuals Treated With Oral Insulin , 2011, Diabetes Care.

[67]  A. Hattersley,et al.  Precision diabetes: learning from monogenic diabetes , 2017, Diabetologia.

[68]  J. Skyler,et al.  Prevention of type 1 diabetes. , 1998, The Medical clinics of North America.

[69]  Roy Taylor,et al.  Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial , 2017, The Lancet.

[70]  R. Naylor.  Economics of Genetic Testing for Diabetes , 2019, Current Diabetes Reports.

[71]  F. Ashcroft,et al.  Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. , 2006, The New England journal of medicine.

[72]  C. Mathieu,et al.  Insulin treatment in IA-2A-positive relatives of type 1 diabetic patients. , 2009, Diabetes & metabolism.

[73]  Kenneth L. Jones,et al.  Effectiveness and safety of long-term treatment with sulfonylureas in patients with neonatal diabetes due to KCNJ11 mutations: an international cohort study , 2018, The lancet. Diabetes & endocrinology.

[74]  Mark S. Anderson,et al.  Introducing the Endotype Concept to Address the Challenge of Disease Heterogeneity in Type 1 Diabetes , 2019, Diabetes Care.

[75]  S. Rich.  Genetics and its potential to improve type 1 diabetes care , 2017, Current opinion in endocrinology, diabetes, and obesity.

[76]  S. Fowler,et al.  Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. , 2002 .

[77]  M. McCarthy,et al.  Gene-Lifestyle Interaction and Type 2 Diabetes: The EPIC InterAct Case-Cohort Study , 2014, PLoS medicine.

[78]  Gad Getz,et al.  Type 2 diabetes genetic loci informed by multi-trait associations point to disease mechanisms and subtypes: A soft clustering analysis , 2018, PLoS medicine.

[79]  J. Ilonen,et al.  Removal of Bovine Insulin From Cow's Milk Formula and Early Initiation of Beta-Cell Autoimmunity in the FINDIA Pilot Study. , 2012, Archives of pediatrics & adolescent medicine.

[80]  D. Tobias,et al.  Prediction and Prevention of Type 2 Diabetes in Women with a History of GDM , 2018, Current Diabetes Reports.

[81]  E. Kang,et al.  Effects of Pro12Ala polymorphism of peroxisome proliferator‐activated receptor γ2 gene on rosiglitazone response in type 2 diabetes , 2005, Clinical pharmacology and therapeutics.

[82]  L. Groop,et al.  Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. , 2018, The lancet. Diabetes & endocrinology.

[83]  No Authors.  Standards of Medical Care in Diabetes — 2021 , 2022, KIDNEYS.

[84]  E. Feskens,et al.  Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. , 2001, Archives of internal medicine.

[85]  B. Shields,et al.  Precision Medicine in Type 2 Diabetes: Clinical Markers of Insulin Resistance Are Associated With Altered Short- and Long-term Glycemic Response to DPP-4 Inhibitor Therapy , 2018, Diabetes Care.

[86]  B. Shields,et al.  A Type 1 Diabetes Genetic Risk Score Can Identify Patients With GAD65 Autoantibody–Positive Type 2 Diabetes Who Rapidly Progress to Insulin Therapy , 2018, Diabetes Care.

[87]  S. Hahn,et al.  Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis , 2013, Diabetologia.

[88]  Mark I McCarthy,et al.  A Global Overview of Precision Medicine in Type 2 Diabetes , 2018, Diabetes.

[89]  T. Hansen,et al.  FTO genotype and weight loss: systematic review and meta-analysis of 9563 individual participant data from eight randomised controlled trials , 2016, British Medical Journal.

[90]  D. Hober,et al.  Enteroviral pathogenesis of type 1 diabetes: queries and answers , 2013, Discovery medicine.

[91]  E. Barrett-Connor,et al.  The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10-year follow-up. , 2015, The Journal of clinical endocrinology and metabolism.

[92]  Anthony J. Payne,et al.  Fine-mapping type 2 diabetes loci to single-variant resolution using high-density imputation and islet-specific epigenome maps , 2018, Nature Genetics.

[93]  M. Rickels,et al.  High residual C-peptide likely contributes to glycemic control in type 1 diabetes. , 2020, The Journal of clinical investigation.

[94]  B. Shields,et al.  Cross-sectional and longitudinal studies suggest pharmacological treatment used in patients with glucokinase mutations does not alter glycaemia , 2013, Diabetologia.

[95]  A. Hattersley,et al.  HNF1B-associated renal and extra-renal disease—an expanding clinical spectrum , 2015, Nature Reviews Nephrology.

[96]  J. Krischer,et al.  Safety and efficacy of autoantigen‐specific therapy with 2 doses of alum‐formulated glutamate decarboxylase in children with multiple islet autoantibodies and risk for type 1 diabetes: A randomized clinical trial , 2018, Pediatric diabetes.

[97]  Mark I. McCarthy,et al.  Variation in the Glucose Transporter gene SLC2A2 is associated with glycaemic response to metformin , 2016, Nature Genetics.

[98]  Samuel E. Jones,et al.  Development and Standardization of an Improved Type 1 Diabetes Genetic Risk Score for Use in Newborn Screening and Incident Diagnosis , 2019, Diabetes Care.

[99]  C. Palmer,et al.  CYP2C8 and SLCO1B1 Variants and Therapeutic Response to Thiazolidinediones in Patients With Type 2 Diabetes , 2016, Diabetes Care.

[100]  A. Hattersley,et al.  Pregnancy outcome in patients with raised blood glucose due to a heterozygous glucokinase gene mutation , 2009, Diabetic medicine : a journal of the British Diabetic Association.

[101]  K. Jablonski,et al.  Genetic Predisposition to Weight Loss and Regain With Lifestyle Intervention: Analyses From the Diabetes Prevention Program and the Look AHEAD Randomized Controlled Trials , 2015, Diabetes.

[102]  B. Shields,et al.  Maturity-onset diabetes of the young (MODY): how many cases are we missing? , 2010, Diabetologia.

[103]  J. Florez,et al.  Heterogeneous Contribution of Insulin Sensitivity and Secretion Defects to Gestational Diabetes Mellitus , 2016, Diabetes Care.

[104]  A. de Leiva,et al.  Adult-Onset Autoimmune Diabetes in Europe Is Prevalent With a Broad Clinical Phenotype , 2013, Diabetes Care.

[105]  L. Williams,et al.  Differing effects of metformin on glycemic control by race-ethnicity. , 2014, The Journal of clinical endocrinology and metabolism.

[106]  B. Shields,et al.  A Type 1 Diabetes Genetic Risk Score Can Aid Discrimination Between Type 1 and Type 2 Diabetes in Young Adults , 2015, Diabetes Care.

[107]  I. Tkáč,et al.  Variants in Pharmacokinetic Transporters and Glycemic Response to Metformin: A Metgen Meta‐Analysis , 2017, Clinical pharmacology and therapeutics.

[108]  Claude Bouchard,et al.  Genome-wide physical activity interactions in adiposity. A meta-analysis of 200,452 adults , 2017 .

[109]  Y. Jacquemyn,et al.  Characteristics and pregnancy outcomes across gestational diabetes mellitus subtypes based on insulin resistance , 2019, Diabetologia.

[110]  Giovanni Malerba,et al.  Refining the accuracy of validated target identification through coding variant fine-mapping in type 2 diabetes , 2017, Nature Genetics.

[111]  B. Lie,et al.  Maternal and Newborn Vitamin D–Binding Protein, Vitamin D Levels, Vitamin D Receptor Genotype, and Childhood Type 1 Diabetes , 2019, Diabetes Care.

[112]  S. Ellard,et al.  Ten years of the national genetic diabetes nurse network: a model for the translation of genetic information into clinical care. , 2014, Clinical medicine.

[113]  D. Wherrett,et al.  Prevention of type 1 diabetes. , 2009, Endocrinology and metabolism clinics of North America.

[114]  Diabetes in the Middle East: Government Health Care Policies and Strategies that Address the Growing Diabetes Prevalence in the Middle East , 2019, Current Diabetes Reports.

[115]  B. Shields,et al.  Evaluating associations between the benefits and risks of drug therapy in type 2 diabetes: a joint modeling approach , 2018, Clinical Epidemiology.

[116]  C. de Beaufort,et al.  Effect of Hydrolyzed Infant Formula vs Conventional Formula on Risk of Type 1 Diabetes: The TRIGR Randomized Clinical Trial , 2018, JAMA.

[117]  T. Biswas,et al.  Ethnic predisposition of diabetes mellitus in the patients with previous history of gestational diabetes mellitus: a review , 2018, Expert review of endocrinology & metabolism.

[118]  L. Dimeglio,et al.  Fall in C-Peptide During First 4 Years From Diagnosis of Type 1 Diabetes: Variable Relation to Age, HbA1c, and Insulin Dose , 2016, Diabetes Care.

[119]  R. Holman,et al.  Effect of race on the glycaemic response to sitagliptin: Insights from the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) , 2018, Diabetes, obesity & metabolism.

[120]  K. Gadde,et al.  Long-Term Weight Loss With Metformin or Lifestyle Intervention in the Diabetes Prevention Program Outcomes Study , 2019, Annals of Internal Medicine.

[121]  M. McCarthy,et al.  Genetic Risk Scores for Diabetes Diagnosis and Precision Medicine , 2019, Endocrine reviews.

[122]  F. Ashcroft,et al.  Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. , 2004, The New England journal of medicine.

[123]  S. Sharp,et al.  Lifestyle Advice Combined with Personalized Estimates of Genetic or Phenotypic Risk of Type 2 Diabetes, and Objectively Measured Physical Activity: A Randomized Controlled Trial , 2016, PLoS Medicine.

[124]  K. Jablonski,et al.  Lifestyle and Metformin Ameliorate Insulin Sensitivity Independently of the Genetic Burden of Established Insulin Resistance Variants in Diabetes Prevention Program Participants , 2015, Diabetes.

[125]  A. Hattersley,et al.  Prediction algorithms: pitfalls in interpreting genetic variants of autosomal dominant monogenic diabetes. , 2019, The Journal of clinical investigation.

[126]  K. Owen.  Monogenic diabetes in adults: what are the new developments? , 2018, Current opinion in genetics & development.

[127]  Robert J. Meyer.  Precision Medicine, Diabetes, and the U.S. Food and Drug Administration , 2016, Diabetes Care.

[128]  B. Shields,et al.  C-Peptide Decline in Type 1 Diabetes Has Two Phases: An Initial Exponential Fall and a Subsequent Stable Phase , 2018, Diabetes Care.

[129]  G. A. Fleming,et al.  Diabetes Digital App Technology: Benefits, Challenges, and Recommendations. A Consensus Report by the European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA) Diabetes Technology Working Group , 2019, Diabetes Care.

[130]  E. Segal,et al.  Personalized Nutrition by Prediction of Glycemic Responses , 2015, Cell.

[131]  T. Barrett,et al.  WFS1 Wolfram Syndrome Spectrum Disorder , 1993 .

[132]  H. Kolb,et al.  The Deutsche Nicotinamide Intervention Study: an attempt to prevent type 1 diabetes. DENIS Group. , 1998, Diabetes.

[133]  J. Krischer,et al.  An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. , 2019, The New England journal of medicine.

[134]  G. Bray,et al.  Effects of Weight Loss, Weight Cycling, and Weight Loss Maintenance on Diabetes Incidence and Change in Cardiometabolic Traits in the Diabetes Prevention Program , 2014, Diabetes Care.

[135]  E. Demerath,et al.  Physical Activity Attenuates the Influence of FTO Variants on Obesity Risk: A Meta-Analysis of 218,166 Adults and 19,268 Children , 2011, PLoS medicine.

[136]  이현철,et al.  Effects of Pro12Ala polymorphism of peroxisome proliferator-activated receptor γ2 gene on rosiglitazone response in type 2 diabetes , 2005 .

[137]  R. Scharfmann,et al.  Activating mutations in the ABCC8 gene in neonatal diabetes mellitus. , 2006, The New England journal of medicine.